within Pharmacolibrary.Drugs.ATC.G;

model G01AG02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 70 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,
    adminCount     = 1,
    Vd             = 0.0066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Terconazole is a triazole antifungal agent primarily used for the treatment of vulvovaginal candidiasis. It is administered as a topical formulation and is FDA-approved for intravaginal use. Its mechanism of action is through inhibition of fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and thus fungal cell membrane formation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult female subjects using intravaginal administration; values are approximated based on summary statements available from product labels and secondary literature, as no detailed compartmental PK modeling for terconazole in humans is published.</p><h4>References</h4><ol><li><p>Iavazzo, C, et al., &amp; Falagas, ME (2011). Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. <i>Journal of women&#x27;s health (2002)</i> 20(8) 1245–1255. DOI:<a href=&quot;https://doi.org/10.1089/jwh.2010.2708&quot;>10.1089/jwh.2010.2708</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21774671/&quot;>https://pubmed.ncbi.nlm.nih.gov/21774671</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G01AG02;
